Journal
PROGRESS IN POLYMER SCIENCE
Volume 33, Issue 10, Pages 998-1012Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.progpolymsci.2008.08.002
Keywords
Silk proteins; Sericin; Fibroin; Cosmetics; Anticancer drugs; Biomaterial
Categories
Funding
- Department of Science and Technology, Department of Biotechnology [BR/PR 6035/MED/14/733/05, BT/PR 9552/ICD/16/755/06]
- Council of Scientific and Industrial Research, Govt. of India
- Indo-US Scientific and Technology Foundation, New Delhi
- Department of Biotechnology, Indian Institute of Technology, Kharagpur
- the Department of Biomedical Engineering, Tufts University
- NIH Tissue Engineering Resource Center [P41 EB002520]
Ask authors/readers for more resources
Silk proteins consist of a fibrous core protein, fibroin, and glue proteins called sericins, which envelop the fibroin fiber with successive sticky layers that help in the formation of a cocoon by cementing together the silk fibers. This system is essentially a protein-fiber composite system, with fibers of the high-molecular-weight fibroin proteins surrounded by the gluelike continuous phase of the sericin. In mulberry silk produced by Bombyx man, Ser1 and Ser2 are the two major genes encoding for sericin. Ser1 is the most abundant silk sericin of B. moli and consists of repeats of a 38-amino acid motif that contributes towards the hydrophilicity of sericin. The protein has partially been characterized from non-mulberry silkworms like the tropical tasar Antheraea mylitta, and studied for various potential applications because of its unique biochemical and biophysical properties. These applications include the skincare and food industries, as coating material for biomedical applications like anticoagulants, in anticancer drugs, for drug delivery, and in tissue engineering. Sericin promotes proliferation of cells when used as a constituent of cell culture in serum-free media. Sericin also supports cell adhesion and proliferation when used in pure form and/or blended in matrices. Sericin films, 3D scaffolds, nanoparticles, composites, conjugated drugs, and recombinant sericins offer potential future options for these needs. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available